{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:41:59Z","timestamp":1778575319647,"version":"3.51.4"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI16\/01085"],"award-info":[{"award-number":["PI16\/01085"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Red de Investigaci\u00f3n en Sida"},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CIBERINFEC\u2014Consorcio Centro de Investigaci\u00f3n Biom\u00e9dica en Red"},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n and Uni\u00f3n Europea\u2014NextGenerationEU","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031015","name":"Hospital Cl\u00ednic, Barcelona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Switching to dolutegravir plus lamivudine has been associated with weight gain. We aimed to assess factors associated with weight gain and changes in body composition in people with HIV switching to dolutegravir plus lamivudine in the DOLAM trial (EudraCT 201500027435).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>People with HIV on suppressive triple therapy were randomized to switch to dolutegravir plus lamivudine or to continue triple therapy. Weight and height were measured, and dual X-ray absorptiometry (DXA) scans were performed at baseline and 48\u2005weeks. Factors associated with 48\u2005week weight change were estimated using linear regression models adjusted for weight at baseline. DXA-derived changes were assessed using age- and sex-adjusted linear or log-linear mixed-effects regression models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>One hundred and eighty (68% of the DOLAM trial participants) (dolutegravir plus lamivudine, n\u200a=\u200a88; triple therapy, n\u200a=\u200a92) participants contributed with paired baseline and 48\u2005week DXA scans. Mean (95% CI) weight changes were 1. 362\u2005kg (0.437\u20132.287) in the dolutegravir plus lamivudine arm and 0.199\u2005kg (\u22120.742 to 1.140) in the triple therapy arm. Treatment with dolutegravir plus lamivudine and age were independently associated with greater weight change at 48\u2005weeks. DXA-derived changes in body fat mass (&amp;lt;0.5% in both arms), lean mass (&amp;lt;7% in both arms) and bone mineral density scans (&amp;lt;0.5% in both arms) did not differ between arms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Although weight at 48\u2005weeks increased with dolutegravir plus lamivudine but not with triple therapy in the DOLAM study, we did not detect any significant DXA-derived changes in body fat, lean mass or bone mineral density between arms.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaf192","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T03:52:05Z","timestamp":1750823525000},"page":"2226-2233","source":"Crossref","is-referenced-by-count":1,"title":["48\u2005Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2614-6545","authenticated-orcid":false,"given":"Elisa","family":"de Lazzari","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic-IDIBAPS , Barcelona ,","place":["Spain"]},{"name":"Department of Medicine, University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvana","family":"Di Gregorio","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolic Diseases, Creu Blanca , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jhon","family":"Rojas","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Althaia, Xarxa Assistencial Universit\u00e0ria de Manresa , Manresa ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adria","family":"Curran","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Vall d\u2019Hebron , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1138-5770","authenticated-orcid":false,"given":"Pere","family":"Domingo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hospital de Sant Pau , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Negredo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Germans Tr\u00edas I Pujol , Badalona ,","place":["Spain"]},{"name":"Fundaci\u00f3 Lluita Contra les Infeccions , Badalona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0073-873X","authenticated-orcid":false,"given":"Juan","family":"Tiraboschi","sequence":"additional","affiliation":[{"name":"Hospital de Bellvitge, L\u2019Hospitalet de Llobregat ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0894-3711","authenticated-orcid":false,"given":"Ana","family":"Gonzalez-Cordon","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic-IDIBAPS , Barcelona ,","place":["Spain"]},{"name":"Department of Medicine, University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1996-4726","authenticated-orcid":false,"given":"Berta","family":"Torres","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic-IDIBAPS , Barcelona ,","place":["Spain"]},{"name":"Hospital de Bellvitge, L\u2019Hospitalet de Llobregat ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abiu","family":"Sempere","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic-IDIBAPS , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexy","family":"Inciarte","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic-IDIBAPS , Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep M","family":"Gatell","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"Medical Affairs Department, ViiV Healthcare , Tres Cantos, Madrid ,","place":["Spain"]},{"name":"Reial Acad\u00e8mia de Medicina de Catalunya , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose L","family":"Blanco","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic-IDIBAPS , Barcelona ,","place":["Spain"]},{"name":"Department of Medicine, University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6911-8846","authenticated-orcid":false,"given":"Esteban","family":"Martinez","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic-IDIBAPS , Barcelona ,","place":["Spain"]},{"name":"Department of Medicine, University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Reial Acad\u00e8mia de Medicina de Catalunya , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the DOLAM study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Abdulghani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Bad\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J L","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Cadafalch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Callau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Comella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Corbacho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Curran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"de Lazzari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z","family":"Escalante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Falc\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Figuerola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Garc\u00eda-Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J M","family":"Gatell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E M","family":"Gonz\u00e1lez de la Fuente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Gonz\u00e1lez-Cord\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M M","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Herrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Inciarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Laguno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Llobet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Mart\u00ednez-Rebollar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M G","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M E","family":"Molas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Mur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Negredo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Paredes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Piatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Planas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Podzamczer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Puig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Puig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Scevola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Silva-Klug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Solbes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Sol\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Teruel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Tiraboschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Torrella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"2025080100171891900_dkaf192-B1","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1016\/S2352-3018(21)00100-4","article-title":"Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48\u2005weeks (DOLAM): a randomised non-inferiority trial","volume":"8","author":"Rojas","year":"2021","journal-title":"Lancet HIV"},{"key":"2025080100171891900_dkaf192-B2","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/cid\/ciac130","article-title":"Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025080100171891900_dkaf192-B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(25)00105-5","article-title":"Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial","author":"Ryan","year":"2025","journal-title":"Lancet HIV"},{"key":"2025080100171891900_dkaf192-B4","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1093\/infdis\/jiae405","article-title":"In-depth analysis of the HIV reservoir confirms effectiveness and safety of dolutegravir\/lamivudine in a phase 4 randomized controlled switch trial (RUMBA)","volume":"231","author":"De Scheerder","year":"2025","journal-title":"J Infect Dis"},{"key":"2025080100171891900_dkaf192-B5","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/cid\/ciae191","article-title":"Antiretrovirals and weight change: weighing the evidence","volume":"79","author":"Wohl","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025080100171891900_dkaf192-B6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1536\/ihj.19-315","article-title":"Association between changes in body weight and fat weight in middle age general population","volume":"61","author":"Itoh","year":"2020","journal-title":"Int Heart J"},{"key":"2025080100171891900_dkaf192-B7","doi-asserted-by":"publisher","first-page":"e666","DOI":"10.1016\/S2352-3018(20)30241-1","article-title":"Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial","volume":"7","author":"Venter","year":"2020","journal-title":"Lancet HIV"},{"key":"2025080100171891900_dkaf192-B8","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1093\/cid\/ciab444","article-title":"Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials","volume":"73","author":"Erlandson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025080100171891900_dkaf192-B9","doi-asserted-by":"publisher","first-page":"e23984","DOI":"10.1002\/ajhb.23984","article-title":"The normal relationship between fat and lean mass for mature (21\u201330\u2005year old) physically fit men and women","volume":"36","author":"Potter","year":"2024","journal-title":"Am J Hum Biol"},{"key":"2025080100171891900_dkaf192-B10","doi-asserted-by":"publisher","first-page":"20170078","DOI":"10.1259\/bjrcr.20170078","article-title":"Body composition, dual-energy X-ray absorptiometry and obesity: the paradigm of fat (re)distribution","volume":"5","author":"Ponti","year":"2019","journal-title":"BJR Case Rep"},{"key":"2025080100171891900_dkaf192-B11","doi-asserted-by":"publisher","first-page":"e13190","DOI":"10.1111\/obr.13190","article-title":"Diagnosis of obesity based on body composition-associated health risks: time for a change in paradigm","volume":"22 Suppl 2","author":"Bosy-Westphal","year":"2021","journal-title":"Obes Rev"},{"issue":"uppl 2","key":"2025080100171891900_dkaf192-B12","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1093\/annonc\/mdx810","article-title":"Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy","volume":"29","author":"Baracos","year":"2018","journal-title":"Ann Oncol"},{"key":"2025080100171891900_dkaf192-B13","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1093\/cid\/ciac827","article-title":"Limited weight impact after switching from boosted protease inhibitors to dolutegravir in persons with human immunodeficiency virus with high cardiovascular risk: a post hoc analysis of the 96-week NEAT-022 randomized trial","volume":"76","author":"Waters","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025080100171891900_dkaf192-B14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2165\/11597140-000000000-00000","article-title":"Current status of body composition assessment in sport: review and position statement on behalf of the Ad Hoc Research Working Group on Body Composition Health and Performance, under the auspices of the I.O.C. Medical Commission","volume":"42","author":"Ackland","year":"2012","journal-title":"Sports Med"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/8\/2226\/63574216\/dkaf192.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/8\/2226\/63574216\/dkaf192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T04:17:24Z","timestamp":1754021844000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/8\/2226\/8173274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":14,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,6,25]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf192","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,6,25]]}}}